SCHEMBL6794827

SCHEMBL6794827

O=C(O)c1ccccc1-c1ccncc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
HNF4A P41235 1/20 0.53
BCAT2 O15382 1/20 0.52
DHODH Q02127 1/20 0.51
CHRNB2 P17787 3/20 0.50
CHRNB4 P30926 3/20 0.50
CHRNA3 P32297 3/20 0.50
CHRNA4 P43681 3/20 0.50
LTB4R2 Q9NPC1 2/20 0.50
ALOX15 P16050 1/20 0.50
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
FABP3 P05413 1/20 0.49
FABP4 P15090 1/20 0.49
FABP5 Q01469 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL9227339 0.90 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL29105027 0.88 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
Phthalic Acid SCHEMBL1649174 0.85 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2NPC1RAB9ADHODH
Benzene SCHEMBL28480917 0.85 HNF4A (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL133057 0.85 HNF4A (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
Benzene SCHEMBL1403559 0.85 HNF4A (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL26624744 0.85 HNF4A (0.69) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL18759613 0.85 HNF4A (0.63) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL30292805 0.85 HNF4A (0.63) ALDH1A1SMN1; SMN2NPC1RAB9AHNF4A
SCHEMBL38663696 0.85 DHODH (0.54) ALDH1A1SMN1; SMN2NPC1RAB9ADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117696012-A Metal organic framework material and preparation method and application thereof 浙江大学 2024-03-15 CN claimed
CN-115304996-B Water-based environment-friendly high-performance UV surface treating agent 广东远东高分子科技有限公司 2022-12-20 CN claimed
CN-115304996-A Water-based environment-friendly high-performance UV surface treating agent 广东远东高分子科技有限公司 2022-11-08 CN claimed
CN-110270233-B Metal organic framework nanosheet mixed matrix membrane and preparation method and application thereof 浙江工业大学 2021-11-23 CN claimed
CN-113185497-A Synthetic method of 3, 6-di (4-pyridyl) -9- (4-pyridylphenyl) -9H-carbazole 运城学院 2021-07-30 CN claimed
CN-111924887-A Preparation method of micron cobalt disulfide composite material 北京科技大学 2020-11-13 CN claimed
CN-109796783-B Zinc porphyrin supermolecule dye sensitizer and preparation method and application thereof 江苏理工学院 2020-10-30 CN claimed
CN-108299478-B Cadmium-based metal organic framework material and preparation method and application thereof 华南师范大学 2020-03-24 CN claimed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 US disclosed
CN-118271516-B Water-resistant room temperature phosphorescence gradient reinforced material and preparation method thereof 广东工业大学 2025-02-11 CN disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 US disclosed
CN-118271516-A Water-resistant room temperature phosphorescence gradient reinforced material and preparation method thereof 广东工业大学 2024-07-02 CN disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 CN disclosed
EP-0575425-B1 USE OF OXAZOLO- 2,3-a]ISOINDOLE AND IMIDAZO 2,1-a]ISOINDOLE DERIVATIVES AS ANTIVIRAL DRUGS, AND NEW OXAZOLO 2,3-a]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1995-10-11 EP disclosed
EP-0569457-B1 USE OF THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES AS ANTIVIRAL MEDICAMENTS AND NOVEL THIAZOLO- [2,3-A]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1995-06-14 EP disclosed
EP-0575425-A1 USE OF OXAZOLO- 2,3-a]ISOINDOLE AND IMIDAZO 2,1-a]ISOINDOLE DERIVATIVES AS ANTIVIRAL DRUGS, AND NEW OXAZOLO 2,3-a]ISOINDOLE DERIVATIVES. BOEHRINGER MANNHEIM GMBH (DE) 1993-12-29 EP disclosed
EP-0569457-A1 USE OF THIAZOLO- 2,3-A]ISOINDOLE DERIVATIVES AS ANTIVIRAL MEDICAMENTS AND NOVEL THIAZOLO- 2,3-A]ISOINDOLE DERIVATIVES. BOEHRINGER MANNHEIM GMBH (DE) 1993-11-18 EP disclosed
WO-1992016207-A1 USE OF OXAZOLO-[2,3-a]ISOINDOLE AND IMIDAZO[2,1-a]ISOINDOLE DERIVATIVES AS ANTIVIRAL DRUGS, AND NEW OXAZOLO[2,3-a]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1992-10-01 WO disclosed
WO-1992013863-A1 USE OF THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES AS ANTIVIRAL MEDICAMENTS AND NOVEL THIAZOLO-[2,3-A]ISOINDOLE DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1992-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885SMN1; SMN2 627/4885NPC1 224/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 ALDH1A1 621/4885SMN1; SMN2 627/4885NPC1 224/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 ALDH1A1 4172/4885SMN1; SMN2 591/4885NPC1 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.